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In the experiments now to be described, we have found that immune serums 
prepared in rabbits with cells of various mouse lymphomas as antigens will not 
only kill several types of lymphoma  cells rapidly in vitro  in  the  presence of 
complement but will act upon them in vivo as well, the effects being to a  con- 
siderable extent specific and dependent upon the presence of an antibody that re- 
acts with neoplastic and non-neoplastic lymphocytic cells of mice. Furthermore, 
the  anti-lymphoma serums  acted more  powerfully upon  the  lymphoma  cells 
in vivo than did such  chemotherapeutic  agents  as  amethopterin,  azaguanine, 
ethionine, azaserine, and 6-mercaptopurine, given singly or in various combina- 
tions in maximal tolerated mounts,  though their effects were not so powerful 
as those exerted by normal guinea pig serum on lymphoma cells of two types 
that are susceptible to its effects in vivo (1). 
Although by no means extensive,  the older work of several investigators provides little 
reason for supposing that heterologous immune serums--that is to say, antiserums made by 
injecting cancer cells into animals of alien species--have the capacity to act powerfully  or 
specifically against cancer cells in ~vo. For example, Borrel in 1907 failed to find antibodies 
that were effective in v~vo against the cells of a mouse carcinoma in immune serums procured 
from sheep and fowls that had been given large quantities of the cancer as antigen (2), and 
Tyzzer in 1916 found that an antiserum produced in rabbits, with mouse sarcoma cells as 
antigen, did not retard growth of the sarcomas even when the antiserum was injected several 
times directly into the subcutaneous tumors, while subsequently Rohdenburg noted that 
an antiserum prepared in guinea pigs with the Flexner-Joblin rat carcinoma as antigen was 
devoid of effect on the tumor in ~o (3). Furthermore, Lambert in 1914 found that guinea 
pigs injected with rat blood or rat embryo skin provided immune serums  that acted quite 
as powerfully against rat sarcoma cells cultured in ~tro as did immune serums made with 
the sarcoma cells as antigens (4), and Lumsden, in an extensive study begun in 1925, found 
* This study was aided by grants from Mr. John W. O'Boyle, The National Cancer Insti- 
tute, and the American Cancer Society, Inc. 
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that immune serums prepared in rabbits with cells from the Jensen rat sarcoma as antigen, 
although toxic for the neoplastic cells when brought into contact with them in vitro, were 
devoid of noteworthy effect in vivo (5). 
Under suitable  conditions,  however, heterologons immune  serums  will inhibit  the cells 
of two transplanted  lymphomas to some extent in vivo. For Nettleship in 1945 showed that 
immune  rabbit  serums  made  with  chemically separated  fractions of Murphy-Sturm  lym- 
phoma cells as antigens, when given in large amounts to rats implanted with the lymphoma 
cells 4  to 5 days previously, brought about regression of the growths in 57 per cent of 41 
treated animals and slowed the growth of the lymphomas in most of the remainder (6). Nettle- 
ship's results are obviously open to the objection, recognized by him, that his animals were 
resistant  to the transplanted  cells employed; even so his findings seem significant, since he 
set up his controls carefully and found that regression occurred in approximately 10 per cent 
of 83 control animals. In further studies, Kidd showed that  an anti-Lymphoma  5C3HED 
immune rabbit serum enhanced the inhibitory effect of normal guinea pig serum on the cells 
of Lymphoma 6C3HED in vivo (1); indeed, the latter effect was discovered incidentally in 
experiments designed to test for inhibition by the immune serum, the guinea pig serum be- 
Lug  added  with  a  view  to  enhancing  its  effect. More  recently,  lgungester  and  Fisher 
have reported  that  immune serums,  prepared  in rabbits  with sedimented materials sepa- 
rated from Lymphoma 5C3HED cells as antigen, inhibited growth of these ceils to a  con- 
siderable  extent  when  injected  Lutraperitoneally  into  the  host  animals  within  48 
hours following implantation of the cells,  but the serums had little or no effect when given 
after 96 to 144 hours (7). 
Lumsden (8), Phelps (9), and Gorer (10) have shown furthermore, that isoantibodies often 
appear in the blood of animals manifesting resistance to cancer cells implanted into hosts 
of alien breeds, while Kidd (11) and Burmester (12) have found that humoral antibodies are 
effective in v~tro and in vivo against cells of the Brown-Pearce rabbit carcinomas and those 
of fowl lymphomatosis, respectively. The observations of Michison (13) and those of Algire, 
Prehn,  and  Weaver (14)  have made it plain, however, that cells of resistant and  immune 
hosts are more influential  than  are humoral isoantibodies in bringing about  regression of 
transplanted  cancer Cells of several types. 
Materials  and Methods 
In brief, 43 lots of pooled immune rabbit serums (hereinafter IRS) were made by injecting 
Frennd's adjuvants pins suspensions of various normal and neoplastic mouse tissues (normal 
kidney,  liver,  brain,  thymus,  lymph nodes,  spleen,  erythrocytes;  transplanted  malignant 
lymphomas  of  seven  types  which  had  originated  in  C3H,  AKR,  and  A  mice,  and  a 
transplanted  mammary carcinoma of C3H mice) into large domestic rabbits.  The immune 
serums thus obtained were then tested, together with serums from normal rabbits, for capac- 
ity to act upon the cells of several transplanted mouse lymphomas in vitro and in ~ivo. 
T~  immune rabbit scrum~ were prepared in a  standardized  way. Mouse tissues of three 
general sorts were used as antigens: (a)  normal mouse organs that were presumably devoid 
of large numbers of lymphocytic cells--brain, kidney, liver, muscle, whole embryos, erythro- 
cytes; (b) non-neoplastic lymphatic organs,  such as thymus,  lymph nodes, and  spleen pro- 
cured from C3H or AKR mice 2 to 3 months old; and (c) the cells of transplanted lymphomas 
of seven different types which  had  originated in either AKR,  C3H, or  A  mice and  been 
carried in host animals of the strain of origin. For further comparison, an immune serum was 
also made with tissue from a transplanted mammary carcinoma which had  recently originated 
in a C3H mouse in this laboratory. The tissue in each instance, usually 50 gin. or more, was 
procured with an aseptic t~hnlque and pressed with a pestle through a 40 mesh monel metal 
sieve into 50 cc. of Ringer's solution; the heavy suspension of cells was then mixed in a com- 
mercial Waring blendor or by means of a hand syringe with Freund's adjuvants (50 cc. falba, S.  C.  MOHOS AND J.  O.  KIDD  235 
50 cc. bayol, and 330 mgm. dried Mycobacterium  bulyricum).  The antigen was injected intra- 
muscularly in six sites in 4 to 10 adult hybrid rabbits  (2.0 cc. to 4.0 cc. in each site, 2.0 to 
10.0  gm.  of tissue  being injected into each animal); large granulomas  regularly appeared 
where the antigen had  been deposited. The animals were bled from the heart on the 21st, 
28th, and 35th days, approximately 60 cc. being removed at each of the first two bleedings, 
and as much blood as possible at the final bleeding. After the final bleedings the serum from 
all rabbits of a given imnmni,ation was pooled, cultured in broth and on agar, and stored in 
the deep freeze at -  16°C. 
As already mentioned, seven transplanted  mouse  lymphomas were employed.  Two of these 
(Lymphomas 6C3HED and E9514)  had originated in C3H mice, three (Lymphomas AKRL1, 
AKR17, and AKR13) in AKR mice, and  two (Lymphomas A1 and ?,2)  in Strong A mice. 
The growths were transferred as routine in young adult mice of the three respective breeds, 
all procured from the Jackson Memorial Laboratory, Bar Harbor.  They grew equally well 
in male and female mice, and progressively until death of the host except in the case of Lym- 
phoma 6C3HED, which regressed after a period of transitory growth in approximately 5 per 
cent of the animals. Suspensions of the lymphoma cells, for Use in routine transfers and in the 
in e/tro and/n v/vo tests to be described further on, were prepared as in previous studies (1), 
briefly as follows: Subcutaneous growths, usually 1.5 to 3.0 cm. across,  which had resulted 
from implantations made 8  to 10 days previously, were procured with aseptic precautions 
and pressed through the 40 mesh monel metal screen into a  buffered-giucose-Ringer's solu- 
tion, in which the pH was adjusted to 7.4 with 0.01M phosphate buffer and to which glucose 
was added in a  concentration of 200  rag. per cent--hereinafter BGR. The suspension was 
allowed to stand a  few minutes in a  cylinder to allow the tissue debris and clumps of cells 
to settle out. From the center of the column the required material was then carefully pipetted 
off  Counts of the cells were made microscopically with an  ordinary hemocytometer, and 
the volume of the suspension was so adjusted that 10 thousand  to 10 million or more cells 
were present in each milliliter. Cultures of the final suspensions in broth and on agar regularly 
proved sterile. For routine transfers, I million or more cells in 0.5 mi. of BGR were implanted 
by means of a  1.0 mi. syringe and 25 gauge needle into the subcutaneous tissue of each groin. 
Palpable lymphomas regularly developed at the implanted sites, usually within 5 to 7 days, 
and these enlarged progressively as a  rule until death of the host animals with generalized 
lymphomatosis.  Microscopic studies  furthermore  showed  that  the  lymphoma  cells spread 
rapidly following the subcutaneous implantations; for example, within 3 to 5 days following 
implantation into the subcutaneous tissues of 3 to 6 week old AKR mice, Lymphoma AKRL1 
cells were often more numerous in lymph nodes throughout the body and in the spleen, liver, 
and other viscera, than at the implanted sites. 
For the in ~4ro Studles, the immune serums, and normal rabbit serum that had been pro- 
cured and stored in the same way, were mixed in suitable dilutions in test tubes with sus- 
pensions  of  the  lymphoma  cells  prepared  as  described  above.  As  a  rule,  the  normal 
and immune rabbit serums were heated at 65°C. for 20 minutes to inactivate complement and 
natural  antibodies; such heating has no deleterious effect on induced antibodies, as much 
experience has shown  (15).  Normal guinea pig serum, pooled from a  dozen or more adult, 
market:bought  guinea pigs and  tested  for  hemolytic activity in  conjunction  with  rabbit 
amboceptor, was usually added to each of the in vitro mixtures in a  final concentration of 
1:10, to provide a uniform quantity of complement. The mixtures were then held 1 hour or 
longer at 37°C., centrifuged at 600 it.P.v, for $ minutes, and the deposited cells resuspended 
in an equal volume of BGR--this to limit contact between serums and cells. To test for viabil- 
ity, the cells of each mixture were then implanted subcutaneously in two or four susceptible 
test mice, with careful charting afterwards of all resulting growths. 
Fop the in vivo tests, 5,000 to 300,000 or more lymphoma cells were first implanted in each 
groin of susceptible, healthy adult mice. After an interval of 1 hour to 6 days or more, the 
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repeated several times, as will be noted in the accounts of the various experiments. The mice 
were carefully observed afterwards, repeated chartings of all growths being made and scru- 
tiny of the animals for toxic effects of the immune serums as well. 
Tests for  Viability  of Mouse  Lympkoma  Cells Exposed  In  Vitro 
in the Presence of Complement to  Various  Immune Serums 
In an initial experiment viability tests were made with Lymphoma AK_RL1 cells 
that had been held in contact during one hour at 37°C. with (a) normal rabbit serum 
and (b) three pooled immune rabbit serums. One of the immune rabbit serums (IRS 
47) had been prepared by injecting a suspension of liver cells from normal C3I-I mice, 
together with Freund's adjuvants, into rabbits; another (IRS 46) with a  suspension 
of cells from thymuses and lymph nodes from normal C3H mice; and the third (IRS 
33) with Lymphoma AKRL1 cells. The serums were first heated at 65  ° for 20 minutes, 
to inactivate complement and  natural antibodies (15).  In each instance the serum 
specimens were  tested  in several dilutions as such  and  with unheated  guinea pig 
serum added in a  final concentration of 1:10 to provide complement. 
Chart 1 shows the results. It can be seen that the heated normal rabbit serum, in 
a final concentration of 1:2, had no effect on the lymphoma cells either alone or with 
added complement. The three heated immune serums likewise proved innocuous for 
the lymphoma ceils in those mixtures that were devoid of guinea pig serum. In the 
presence of guinea pig serum 1 : 10, however, all three of the immune serums rendered 
the  lymphoma  cells non-viable, IRS  47:Anti-liver being  completely effective in  a 
final concentration of 1:2 and nearly so at 1:10 but devoid of effect at 1:50, while 
IRS  46:Anti-thymus-node was considerably more  potent,  and  IRS  33:Anti-Lym- 
phoma AKRL1 was still more so, no tumors resulting from the injection of the mixture 
containing lymphoma cells and this serum in final concentrations of 1:2,  1 : 10, and 
1:50. 
In several additional experiments heated specimens of various immune rabbit serums 
that had been prepared with various normal mouse tissues and with mouse lymphoma 
cells as antigens, regularly killed lymphoma cells of three types (6C3HED,  E9514, 
AKR17) when the serums, diluted 1:40 to 1 : 160, were held in contact with the lym- 
phoma cells for 1 or 2 hours in vitro in the presence of added guinea pig complement; 
but all failed to do so in final concentrations of 1:2 in the absence of complement. 
Hence unheated guinea pig serum was employed as routine in the subsequent in ~itro 
tests. 
Table I shows the outcome of more extensive tests. 15 immune serums--9 prepared 
with various normal mouse tissues as antigens, and 6 with lymphoma cells of several 
types as antigens--were tested for ability to kill lymphoma cells of three kinds during 
exposure in tdtro in the presence of complement. All the immune serums except one 
exhibited some ability to kill the lymphoma cells in vitro in the presence of complement, 
as the table shows. Furthermore the three types of lymphoma cells differed in suscepti- 
bility, 6C3HED cells being most suceptible to the effects of the various serums, E9514 
cells slightly less so, and AKRL1 cells comparatively  insusceptible. Serums that were 
most potent against 6C3HED  cells (IRS 58 and IRS 35) likewise acted powerfully 
against E9514 and AKRL1 cells, while serums that were least potent against 6C3HED 
cells (IRS 54 and 66) had comparatively little ability to kill the E9514 and AKRL1 CHA~T 1.  Tests for viability of Lymphoma AKRL1 cells exposed in ritro  to specimens of heated immune rabbit 
serums as such and with added guinea pig serum (complement). 
IRS m immune rabbit serum. So, too, in the charts that follow. 
The rabbit serums were heated in the undiluted state at 65°C.  for 20 minutes immediately before use to inactivate  complement and natural 
antibodies. 
The test mixtures were heated one hour at 37°C prior to implantation. 
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TABLE  I 
Tests .for ViabiHLy o/Lymph~ma Ce/Js of Tkree Types Expose,  d in Vitro in ~l~s  Pre~ac,  e of Comfl~  to Various 
Immune Rabbit Serums 
Outcome of tests for viability 
In vitro mixtures 
6C3HED  cells  !  E9514 cells  ]  AKRLI cells 
4 
I  ! 
Lymphoma ceils (6 million/cc,) 
and guinea pig serum  (com- 
plement)  1:5,  plus  an  equal 
part of:- 
(1) Normal rabbit serum 
(2) IRS 53:anti-AKR muscle 
(3)  IRS 54:anti-C3H embryo 
(4) IR$ 66:anti-C3H RBC 
(5) IRS 47:anti-AKR liver 
(6)  IRS 50:anti-AKR kidney 
(7) IRS 52:anti-AKR brain 
(8) IRS 57:anti-C3H thyd-n+s 
(9)  IRS 45:anti-C3H spleen 
(10)  IRS 46:anti-C3H thy d- n 
(11)  IRS 58:anti-Lyre AKRL1 
(12) IRS 35:anti-Lyre AKR17 
(13)  IILS  63:anti-Lyre  A2 
(14)  IRS 60:anti-Lyre  AI 
(15) IRS 49:anti-Lyre 6C3HED 
(16)  IRS 62:anti-Lyre E9514 
Final dilutions of lerums 
1:5  1:20  1:80  1:320 
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IRS ~  immune rabbit serum. The test serums were first heated at 65  ° for 20 minutes, then diluted I: 2.5 to 1:160 with BGR, and added to thr 
tubes containing respectively  the three types of lymphoms cells and complement. The mixtures were next incubated 2 hours at 37". The miffitul 
containing 6C3HED and AKRLI cells were centrifuged at 600 LP.M. for 5 minutes with resuspension of the sedimented cells in BGR immediate 
prior to implantation--thls to limit contact between the cells and serums. The resuspended cells from each mixture  were implanted in two susce 
tible mice (C3H mice for 6C3HED and E9514 cells and AKR mice for AKRLI cells). Each mixture containing E9514 cells was implanted direc~ 
into two susceptible C3H mice. 
thy d- n d- s m  thymus plus node plus spleen. 
Growth of the 6C3HED  cells was recorded according to the following scale:-- 
d-d-d-d-, palpable growths approximately 1.0 cm. in dlameter  appearing in both test mice by the 10th day, enlaxging  progressively  thereaft¢ 
d-d-d-, growths approximately 1.0 cm. in diameter appearing in both test mice by the 12th day. 
d-d-, growths approximately 1.0 cm. in diameter appearing in both test mice by the 14th day. 
d-, growths approximately 1.0 cm. in diameter appearing in both test mice by the 16th day. 
d:, growth approximately 1.0 cm. in diameter appearing in one mouse by the 16th day. 
0, no growth during observation period (16 days in this experiment). 
Growths from implantation of the control mixtures containing E9514 cells  appeared approximately  4 days later than those from eorrespondiz 
mixtures containing 6 C.3HED cells, while the AKRLI ceils in the control mixtures gave rise to tumors 1.0 cm. across on the 8th day.  Arbitral 
scale adjusted accordingly. In all instances the tumors enlarged progressively  throughout the observation period. S.  C.  MOHOS  AND  J.  O.  KIDD  239 
cells, while the other serums fell more or less regularly in between these extremes. In 
general, it will be noted, the immune serums prepared with the several types of lym- 
phoma cells as antigens, and those made with cels from the lymphatic organs of mice, 
were more powerful than the serums prepared with antigens composed of mouse em- 
bryo (IRS 54), erythrocytes fIRS 66), liver  (IRS 47), kidney  (IRS 50),  and brain 
(IRS 52) respectively, while that prepared with muscle as antigen (IRS 53) was devoid 
of effect. More will be said further on about the spedfidty of the antibodies responsible 
for the in vitro effects and about the susceptibility of lymphoma cells of different types. 
The findings given in Chart 1 and Table I are representative of our experience as a 
whole. All told, 36 pooled immune serums--somewhat more than half prepared with 
antigens made from mouse lymphoma cells and the rest with normal mouse tissues as 
antigensmwere  tested  for ability  to kill  lymphoma cells  of several  sorts in vitro. 
Regularly the immune serums prepared with lymphoma cells as antigens, and those 
made with cells from non-neoplastic lymphatic organs of mice (thymus plus lymph 
nodes, occasionally spleens),  proved potent; and in general  they  were more potent 
than immune serums prepared with antigens made from mouse cells of other sorts, 
notably mouse erythrocytes or suspensions of cells from mouse brain, kidney, liver, 
or whole embryos. The findings bear out and extend observations previously made by 
Dulaney and Aruesen (16)  and by Werder, Kirschbaum,  MacDowell, and Syverton 
(17)  on the effects  of rabbit antiserums on leukemic cells in vitro. Furthermore,  the 
fact that the immune serums of the present work were prepared in a  standardized 
way, as already described, gives added weight to the possibility that the differences 
in potency might be meaningful. Absorption tests, now to be described, provide further 
evidence on this point. 
Evidence  That Antibodies  of More  Titan One  Sort Are Responsible 
for  tke in  Vitro Effects:  Results of Tests u,  itk Absorbed  Sera 
In the experiment of Chart 2, an unabsorbed specimen of IRS 37 :Anti-mouse liver, 
in final dilutions of 1:40, 1:80, and 1:160, rendered non-viable all the AKRL1 and 
AKR17 lymphoma cells which were brought into contact with it in the presence of 
complement. When absorbed with mouse liver, however, the serum had no effect on 
either type of lymphoma cells, and the same proved true of a specimen of this serum 
that had been absorbed with Lymphoma AK_RLI cells. Two anti-lymphoma immune 
serumsmIRS 36 and IRS 35, prepared respectively with AKRL1 and AKR17 lym- 
phoma cells as antigens--when used in the unabsorbed state and tested in dilutions 
1:40, 1:80, and  1:160, likewise  killed all the AKRL1 and AKR17 cells in the test 
mixtures.  Absorption of these two serums with the preparation of mouse liver cells 
did not alter their ability to kill the two types of lymphoma cells, though absorption 
with AKRL1 cells rendered the serums innocuous, as the chart shows. 
The results  of more extensive tests  of similar  sort are shown in Tables  II, III, 
and IV. 
Considered with the findings of the preceding section, the results of the absorption 
tests make it plain that antibodies of at least two sorts are responsible for the in vitro 
effects: (a) antibodies that appear in the blood of rabbits injected with cells from any 
one of a  variety of non-neoplastic mouse tissues  (e.g., liver, kidney, brain, embryo, 
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CHART 2. Tests  for  viability  of  Lymphoma AKRLI  cells  exposed  in  ~ro in  the  presence  of  complement  to unab- 
sorbed  and  absorbed  specimens  of  various  immune serums. 
The rabbit serums were heated in the undiluted state at 6.5°C. for 20 minutes immediately before use. 
For absorption, approximately 25  million lymphoma cells, twice-washed in Ringer's solution, and approximately twice as many liver cells 
prepared  in the same  way from 3 months old AKR mice were used per milliliter of serum 1:20. The absorption  mixtures were incubated  at 
37°C. for I hour, spun at 4,000 R.P.•.  for 20 minutes, and the supernatant  liquids dliuted as shown with BGR. 
The test mixtures were held one hour at 37°C. prior to implantation. 
Concurrent  tests with  the same unabsorbed  and absorbed  serum specimens in mixture with  Lymphoma  AKR17 cells yielded identical 
results. S.  C.  MOHOS  AND  J.  G,  KID])  241 
TABLE  II 
Tests  for  Viability  of Lymphoma  AKRL1  Cells  Exposed  in  Vitro  in  tke  Presence  of  Complement  to  Unabsorbed  and 
Absorbed  Specimens  of  Various  Immune  Serums 
In  vitro  mixtures  Outcome  of tests  for  viability 
Lymphoma AKRLI Cells (3 million/cc.) and guinea pig serum (1:5) plus an equal 
volume of: 
(I)  Normal rabbit serum, 1:10 
(2)  IRS 57:anti-AKR mouse liver, 1:10--unabsorbed 
(3)  "  "  "  "  "  "  "  --absorbed with AKR kidney cells 
(4)  "  "  "  "  "  "  "  --absorbed with AKR liver cells 
(5)  "  °'  "  "  "  "  "  ---absorbed with C3H spleen cells 
(6)  "  "  "  "  "  "  "  --absorbed with C3H thymus-node ceils 
(7)  "  "  "  "  "  "  "  --absorbed with AKRLI ceils 
(8)  IRS 42: anti-C,3H mouse spleen, 1:10--unabsorbed 
(9)  "  "  "  "  "  "  "  --absorbed with AKR kidney ceils 
(10)  "  "  "  "  "  "  "  --absorbed with AKR liver cells 
(11)  "  "  "  "  "  "  "  ---absorbed with C3H spleen cells 
(12)  "  "  "  "  "  "  "  --absorbed with C3H thymus-node ceils 
(13)  "  "  "  "  "  "  "  --absorbed with AKRL1 cells 
(14)  IRS 38:  anti-AKR mouse spleen-thymus-node, 1:10--unabsorbed 
(15)  "  "  "  "  "  "  "  "  "  --absorbed with AKR kidney cells 
(16)  "  "  "  "  "  "  "  "  "  --absorbed with AKR liver cells 
(17)  "  "  "  "  "  "  "  "  "  --absorbed with C3H spleen cells 
(18)  "  "  "  "  "  "  "  "  "  --absorbed  with  C3H  thymus-node 
cells 
(19)  IRS 38:  "  "  "  "  "  "  "  ---absorbed with AKRLI cells 
(20)  IRS 31: unti-Lymphoma 6C3HED, 1:10--unabsorbed 
(21)  "  "  "  "  "  "  ---absorbed with AKR kidney cells 
(22)  "  "  "  "  "  "  ----absorbed  with AKR liver cells 
(23)  "  "  "  "  "  "  --ltbsorbed with C3H spleen cells 
(24)  "  "  "  "  "  "  ---absorbed with C3H thymus-node cells 
(25)  "  "  "  "  "  "  --absorbed with AKRLI cells 
(26)  IRS 34:anti-Lymphoma AKRLI, 1:10--uuabsorbed 
(27)  "  "  "  "  "  "  ---absorbed with AKR kidney cells 
(28)  "  "  "  "  ....  --absorbed with AKR liver cells 
(29)  "  "  "  "  "  "  --absorbed with C3H spleen cells 
(30)  "  "  "  "  "  "  --absorbed with C3H thymus-node cells 
(31)  .....  '  ......  --absorbed with AKRLI cells 
(32)  IRS 43: unti-AKR mouse thymus-node, 1:10--unabsorbed 
(33)  "  "  "  "  "  "  "  "  --absorbed with AKR kidney cells 
(34)  ................. absorbed with AKR liver ceils 
(35)  "  "  "  "  "  "  "  "  --absorbed with C3H spleen cells 
(36)  "  "  "  "  "  "  "  "  ---absorbed with C3H thymns--nede ceils 
(37)  "  "  "  "  "  "  "  "  --absorbed with AKRL1 cells 
Finaldi~tionsofserums 
1:20  1:40  1:~  1:1~ 
++++  ++++  ++++  ++++ 
o  0  o  +++ 
++++  ++++  ++++  -i-+++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
o  o  o  ++ 
++++  ++++  ++++  ++++ 
+++  +++  ++++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
÷+++  ++++  ++++  ++++ 
0  0  0  0 
o  o  o  + 
o  o  +  +++ 
++  ++  ++  ++++ 
+  +  +++  ++++ 
++++  ++++  ++++  ++++ 
0  0  0  0 
o  o  ±  + 
o  o  o  + 
++  ++  ++÷  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
o  o  o  ++ 
o  o  o  -t-+ 
o  o  o  ++ 
+  +  +++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
0  0  0  0 
0  0  0  0 
0  0  0  0 
o  o  +  ++ 
+++  +++  ++++  ++-I-+ 
++++  ++++  ++++  ++++ 
Rabbit sera heated at 65"C. for 20 minutes immediately before use. The absorption mixtures contained respectively 30 million lymphoma 
cells, 25 miliion  thymus-node cells, and approximately twice as many cells from the other organs per cubic centimeter, They were incubated 
at 37°C. for I hour, spun at 4000 n.P.u, for 20 minutes, and the supernatant liquids diluted as shown. For the viability studies, the test  mix- 
tures were held I hour at 37°C.  prior to implantation of 0.5 cc. of each mixture into two test mlce. 
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TABLE  HI 
Tests for Viability  o/Lymphoma AKRLI and 6C3HED Cells Exposed in Vitro in the Presence of Complement to 
Unabsorbed and Absorbed Specimens of Various Immune Serums 
Outcome  of tests for viability 
In vitro mixtures 
AKRL1  cells  6C3HED  ceils 
Lymphoma  cells (3 miliion/cc.) and guinea pig serum  (1:5) 
plus an equal part of: 
(1)  Normal  rabbit serum,  1:20 
(2)  IRS 38: anti-AKR  mouse  thymus-node-spleen,  1:20--unabsorbed 
O)  "  "  "  "  "  "  "  "  "  --absorbed  with AKR  spleen cells 
(4)  "  "  "  "  "  "  "  "  "  --absorbed  with AKR  thymus-node 
cells 
(5)  IRS 38:  "  "  "  "  "  ..... absorbed  with AKRL!  ceils 
(6)  "  "  "  "  "  "  "  "  "  --absorbed  with 6C3HED  cells 
(7)  IRS 27:anti-Lymphoma  AKR  17, l:20--unabsorbed 
(8)  "  "  "  "  "  "  "  ---absorbed with AKR  spleen cells 
(9)  "  "  "  "  "  "  "  --absorbed  with AKR  thymus-node  cells 
(I0)  "  "  "  "  "  "  "  --absorbed  with AKRL1  cells 
(It)  .  "  "  "  "  "  "  --absorbed  with 6C3HED  cells 
(12)  IRS 31:anti-Lymphoma  6C3HED,  1:20---unabsorbed 
(13)  "  "  "  "  "  "  --absorbed  with AKR  spleen cells 
(14)  "  "  "  "  "  "  --absorbed  with AKR  thymus-node  cells 
(15)  "  "  "  "  "  "  --absorbed  with AKRL1  cells 
(16)  "  "  "  "  "  "  ---absorbed  with 6C3HED  cells 
(17) IRS 30:anti-Lymphmna  AKR  13, l:20--uuabsorbed 
(18)  "  "  "  "  "  "  "  ---absorbed with AKR  spleen cells 
(19)  "  "  "  "  "  "  "  --absorbed  with AKR  thymus-node  cells 
(20)  "  "  .....  '  "  "  --absorbed  with AKRL1  ceils 
(21)  "  "  "  "  "  "  "  --absorbed  with 6C3HED  cells 
(22)  IRS 34:anti-Lymphoma  AKRLI,  l:20--unsbsorbed 
(23)  "  "  "  "  "  "  ---absorbed with AKR  spleen cells 
(24)  ............  --absorbed  with AKR  thymus-node  cells 
(25)  "  "  "  "  "  "  --absorbed  with AKRL1  cells 
(26)  ......  "  "  "  ---absorbed with 6C3HED  cells 
Finaldi~tions~serums 
1:~  1:1~  1:~  1:1~ 
++++  ++++  ++++  ++++ 
0  0  0  0 
+  +++  ~  ++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
0  0  0  0 
+  +  o  o 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
0  0  0  0 
o  ++  o  o 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
o  o  o  + 
++++  ++++  o  ++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++÷+  ++++ 
++++  ++++  ++++  ++++ 
0  o  0  ++ 
++++  ++++  ++++  ++++ 
++++  ++++  +++÷  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
Rabbit  sera heated at 65°C. for 20 minutes immediately before use. The absorption mixtures contained respectively 50 million spleen cells, 
100 million thymus-node  cells, and 25 million lymphoma cells per cc. They were incubated 1 hour at 37 C., then  centrifuged.  For the viability 
studies  the mixtures  were held  1 hour at  37°C.,  then  implanted  as such,  0.5  cc. into each of two susceptible mice  (AKR and  C3H, respec- 
tively). 
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TABLE  IV 
Teats for  Viabi~y  of Lymphoma  6C3HED  and  AKRLI  Cells  Exposed  in  Vitro  in  the  Presence  of  Complement  to 
Unabsorbed  and Absorbed  Specimens  of Vat.us  Immune  S~ 
In  vitro  mixtures  Outcome  of  tests  for  viability 
Lymphoms 6C3HED cells (3 million/ce.) and guinea pig serum (1:5) 
plus an equal part oI: 
(1)  Normal rabbit serum, l:10--unabsorbed 
(2)  ........  --absorbed with Swiss RBC 
(3)  "  "  "  "  --absorbed with Swiss liver cells 
Finsldilutionsofserun~ 
1:20  1:40  1:80  1:160 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
o  o  +  ++++ 
++++  ++++  ++++  ++4-+ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
o  ++  +++  ++++ 
o  o  ~  ++++ 
o  o  +++  ++++ 
o  o  +++  ++++ 
o  o  +  ++++ 
o  o  +  ++++ 
(4)  " 
(5)  " 
"  "  "  --absorbed with Swiss kidney ceils 
"  "  "  --absorbed with Swiss muscle cells 
(6)  IRS 48: antI-AKR-RBC,  I: 10--unabsorbed 
(7)  "  "  ........  --absorbed with Swiss RBC 
(8)  "  "  "  "  ....  --sbsorbed with Swiss liver cells 
(9)  "  "  "  "  "  "  ---sbsorbed with Swiss kidney cells 
(10)  "  ' .........  --absorbed with Swiss muscle cells 
(11)  IRS 58:anti-Lymphoma AKRL1, 1:10---unabsorbed 
(12)  "  "  "  "  "  "  ---absorbed with Swiss RBC 
(13)  "  "  "  "  "  "  --absorbed with Swiss liver cells 
(14)  "  "  "  "  "  "  --absorbed  with Swiss kidney cells 
(15)  ...........  '  --*absorbed with Swiss muscle cells 
Lymphmna AKRLI ceils (3 million/cc.) and guinea pig serum (1:5) 
pins an equal part of: 
(16)  Normal rabbit serum, 1:10 
(17) IRS 59:anti-AKR kidney,  1:10---unabsorbed 
(18)  "  "  "  "  "  "  --absorbed  with AKR RBC 
(19)  "  "  "  "  "  "  --absorbed with sheep RBC 
(20)  IRS 47:anti-AKR liver, l:10--u~bsorbed 
(21)  "  "  "  "  "  "  --absorbed with AKR RBC 
(22)  IRS 48:anti-AKR RBC, l:10--unabsorbed 
(23)  ..........  '  ---absorbed with AKR RBC 
(24)  IRS 43:nnt~AKR thymus-lymph nodes,  l:10--unsbsorbed 
(25)  "  "  "  "  "  "  "  "  ---absorbed with AKR RBC 
(26)  "  "  "  "  "  "  "  "  --absorbed with sheep RBC 
"t(27)  IRS 55:anti-Lymphoma AKRLI, 1:10--unabsorbed 
(28)  "  "  "  "  "  "  --absorbed with AKR RBC 
(29)  "  "  "  "  "  "  ---absorbed with AKR kidney cells 
(30)  "  "  "  "  "  "  --absorbed with sheep RBC 
++++  ++++  ++++  ++++ 
o  0  o  ++++ 
++++  ++++  ++++  ++++ 
o  o  o  ++++ 
o  o  ++++  ++++ 
++++  ++++  ++++  ++++ 
o  o  o  + 
++++  ++++  ++++  ++++ 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
The rabbit sera were heated in the undiluted  state at (~°C. for 20 minutes immediately before use. 
In the tests with Lympboma 6CJHED cells, the absorption mixtures contained  approximately 0,6 cc. of packed cells per cubic centimeter 
of serum I:I0. They were incubated at 37°C. for I  hour, spun at 3,000  I.I,.M. for 20 minutes, and the supernatant  liquids diluted Jut shown. 
For the viability studies the test mixtures were held 2 hours at 37°C. and spun at 500 z.P.K, for 8 minutes,  the supernatant  liquids being dis- 
~u°ded  and the cells resuspended in BGR prior to implantation  into two susceptible CJH mice. 
In the tests with AKRLI cells the absorption mixtures contained approximately 0.2 of packed mouse erythrocytes or 0.4 ce. of  packed sheep 
erythrocytes,  or 0.4 cc. of packed kidney cells per cc.  of serum,  1:10. Rest of procedure  as above  except that susceptible AKR mice were 
used in the tests for viability. 
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or kidney cells or mouse erythrocytes; and (b) antibodies that appear in the blood of 
rabbits injected with neoplastic and non-neoplastic lymphoid tissues of mice  (e.g. 
lymphomas, normal thymus +  normal lymph nodes), which are not absorbed from 
the serums by mouse liver cells, mouse kidney cells, or mouse erythrocytes but are 
readily absorbed by mouse lymphoma cells and to some extent also by cells procured 
from the thymuses and lymph nodes of normal mice. The distinction has importance 
for an understanding of the in vivo results, which will be given next. 
Tests for  Effects  of  the  Immune  Serums  on  Mouse  Lymphoma  Cells  in  Viva 
In the experiment of Chart 3 two anti-lymphoma  serums and a specimen of normal 
rabbit serum were injected iatraperitoneally into groups of AKR and C3H mice that 
had  been implanted subcutaneously with  AKRL1  and  6C3HED  lymphoma cells 
respectively. The two immune serums inhibited growth of the lymphoma cells of both 
types either completely or almost completely, while the normal rabbit serum had no 
effect on them. 
Table V shows the results of a larger experiment in which 14 immune serums were 
tested for ability to inhibit growth of Lymphoma AKRL1 cells in vivo. The four anti- 
lymphoma immune serums were all markedly inhibitory, and two of the three immune 
serums made with non-neoplastic lymphoid tissues as antigens were also effective, 
though less so than the anti-lymphoma  serums, while the third was toxic and brought 
about death before the 5th day of all three of the mice into which it was injected. 
None of the 6 immune serums prepared with antigens made from normal mouse organs 
--brain, kidney, liver, embryo--inhibited growth of  the lymphoma cells,  however, 
and the same was true of an immune serum (IRS 59) for which ceils from a mammary 
carcinoma of C3tt mice had been employed as antigen. 
In a number of additional experiments immune serums prepared in rabbits with antigens 
composed of cells from various non-lymphoid organs and tissues of mice all regularly failed 
to inhibit lymphoma cells of four types (6C3HED, E9514, AKRL1, AKR17) in fifo, while 
immune serums made with antigens containing cells of normal lymphoid organs of mice-- 
notably thymus and lymph nodes--usually exhibited some inhibitory effect. In contrast, 
21 pools of anti-lymphoma immune rabbit serums, made with mouse lymphoma cells of one 
or another of the seven types as antigens, all proved notably inhibitory for the 4 types of 
lymphoma cells in vivo when given within a few days following implantation. The anti-lym- 
phoma serums varied considerably in potency, however, and they often proved more effec- 
tive against lymphoma cells of the type employed as antigen than against other  types  of 
lymphoma cells. 
The inhibition  in v/so  was influenced by other factors  as well.  For example, when  rela- 
tively small numbers of lymphoma cells  (e.g.  5,000 to 50,000) were implanted in each groin 
of susceptible  mice, and 1.0 cc. of any one of the various anti-lymphoma immune serums 
was given intraperitoneally  on the  same day, the  lymphoma cells  nearly always failed  to  grow; 
but when larger numbers of cells were implanted (e.g., 300,000 or more), or if the serum injec- 
tions were delayed 3 days or more, inhibition was often incomplete even when larger injec- 
tions of immune serum were given repeatedly. Furthermore,  the lymphoma cells varied in 
susceptibility, those of Lymphoma 0C3HED and E9514 being more or less readily inhibited 
in ~ivo by a variety of anti-lymphoma immune  serums, while those of AKRL1 were influenced 
much less readily, as will be brought out further on. s. c. ~o~os  AND  j. o. mind  245 
Cn~tT 3. Tests  for  effects  in  ~/vo  on  Lymphoma AKRLI  and 5C3HED  cells  of  immtlne serums  prepared in  rab- 
bits  with  lymphoma cells  of  the  two types  as  antigens. 
L, R, -  left and right groins,  respectively. 
The C3H mice were glven 2.0 cc, of the respective sertwas aud the AKR mice 1.0 cc. of the respective serums plus 1,0 co. of  Ringer's solu- 
tion on days I, 2, and 3. 
The serums were heated at 6S°C. for 20 minutes immediately  before use. 
* Remained lively and devoid of tumom  throughout observation period (42 days). TABLE  V 
Tests for Effects in  Vivo of Immune Serums Prepared in Rabbits with Lympkoma  Cells 
and Norma~ Mouse Tissues as Antigens 
Outcome of implantations 
Serums given intraperitoneally to mice of 
respective groups on days 1, 2, and 3  300,000 AKRL1 cells implanted on day 1 in left and right 
groins of 3 AKR test mice (a), (b) (¢) in each of 16 groups 
(I) Nil-untreated controls 
(2) Normal rabbit  serum 
0)  IRS 58:anti-Lymphoma AKRLI 
(4)  IRS 55:anti-Lymphoma AKRL1 
(5)  IRS 63:anti-Lymphoma A2 
(6)  IRS 60:anti-Lympboma AI 
(7)  IRS 57:anti-C3H thymus Jr node Jr spleer 
(8)  IRS 45:anti-C3H spleen 
(9)  IRS 43:anti-AKR thymus Jr node 
(10)  IRS 53:anti-AKR brain 
(11)  IRS 50:anti-AKR kidney 
(12)  IRS 47:anti-AKR liver 
(13) IRS 51:anti-AKR liver 
(14) IRS 44:anti-C3H kidney 
(15)  IRS 54:anti-C3H embryo 
(16)  IRS 59:anti-C3H mammary carcinoma 
Testmice 
(a)  (b)  (c) 
++++  ++++  ++++ 
Jrjr+jr  +++jr  ++++ 
0  d5  d15 
o  +jr  Jr+ 
o  o  Jrjr 
o  o  ++++ 
d4 
0  ++  ++ 
o  Jr+  +jrjr+ 
+jrjrjr  ++++  +++jr 
+-l,jr+  +++jr  ++++ 
++++  ++++  ++++ 
++++  ++++  ++++ 
++++  ++++  ++++ 
++++  ++++  ++++ 
++++  ++++  dl0 
The serums were heated at 65°C. for 20 minutes immediately before use.  Serums IRS  55 and IRS 50 were 
given in amounts of 0.25 cc. to each test mouse on the 3 successive days. The rest were given in  amounts of 0.5 
cc., the total volume in each instance being made up to 2.0 cc. with Ringer's solution. 
-l-{--{--l-I-jr,  died with large tumors in groins and signs of visceral lympbomatosis before day 20. 
-t-jr  , developed lymphoms in only one groin; survived 20 days. 
0  , groins devoid of palpable  tumors, no sign of visceral lymphomatosis during  observation  period 
(20 days). 
d2, dS, etc. =  died on day indicated by numeral. So, too, in the tables that follow. 
TABLE  VI 
Comparative Effects of Unabsorbed  and Absorbed Anti-Lympkoma Immune Serums on AKRL1 Cells in Vivo and in Vitro 
Test serums 
(1) Normal rabbit serum 
(2)  "  "  "  --absorbed with Swiss RBC 
(3)  "  "  "  --absorbed with AKRL1 cells 
(4)  "  "  "  --absorbed with 6C3HED cells 
(5)  IRS 58:snti-AKRLl--unebsorbed 
(6)  "  "  "  "  --absorbed with Swiss RBC 
(7)  "  "  "  "  --absorbed with AKRLI cells 
(8)  "  "  "  "  --absorbed with 6C3HED cells 
(9)  IRS 61: anti-6C3HED--unabsorbed 
(10)  "  "  "  "  --absorbed with Swiss RBC 
(11)  "  "  "  "  --absorbed with AKRL1 cells 
(12)  "  "  "  "  --absorbed with 6C3HED cells 
Growth of AKRL1  cells in 
treated mice. 50~000 AKRLI 
ceils implanted xn each groin 
of three test mice ((a)i  (b), (¢)) 
in each experimental group: 
1.0 cc. of test serums given 
intraperitoneatly to each mouse 
on days 1, 2, 3. 
Testmice 
(a)  ~)  6) 
+-l,jr+  Jr++jr  Jr+jrjr 
++jrjr  Jrjrjrjr  +++jr 
Jrjrjrjr  Jrjrjrjr  Jrjr+jr 
Jrjrjrjr  Jrjrjrjr  +jr+jr 
o  o 
0  ~  d3 
Jrjrjr  ++++  Jr-l.jr+ 
Jrjrjrjr  ~  d8 
o  o  ++++ 
o  o  ++++ 
o  +++  ++++ 
+++  ++++  ++++ 
Growth of AKRL1 cells exposed in w/tro 
to the various immune serums plus 
normal guinea pig serum t: 10 
(complement). 
Final dilutions of serums: 
1:8  1:16  1:32  1:64 
Jrjrjrjr  Jrjrjrjr  ++-4-+  +++-I- 
Not tested 
0  0  0  0 
0  0  0  0 
0  0  o  Jr 
o  0  +jr+  +jr+ 
0  0  0  0 
0  0  0  0 
Jrjrjr  Jr+jr  Jr++  +jrjr 
Jrjrjr  Jrjrjr  Jr+jr  Jrjrjr 
The rabbit sera were heated at 65°C. for 20 minutes before use. Approximately 1.5 cc. of packed erythrocytes  and  6C3HED cells, and 
approximately 1 cc. of packed AKRL1 cells were used per milliliter of serum in the absorption procedures, which were carried out in two steps, 
each 1 hour at 57°C. 
For the in eitro tests, mixtures containing 5 million AKRLI cells and 0.1 cc. guinea pig serum in 1 cc. of the respective serum dilutions 
were incubated in ~/#ro for 16 hours at 37°C., following which they were centrifuged, with  resuspenslon of the cells in the same volume of 
BGR. 0.5 cc. of each suspension was implanted at different sites in two AKR test mice. The findings are recorded as in Table I. 
For the in ~ivo tests, the findings are recorded as follows:-- 
Jr-{--I--t-,  lymphomas in both groins reaching 1.0 cm. across on day 9, enlarging progressively thereafter until death of the host. 
Jr-F't-  ,  lymphomas in both groins reaching 1.0 cm. across on day 11, enlarging progressively thereafter. 
Jr  , lymphoma in one groin; survived 20 days. 
0  , negative throughout observation period (40 days). 
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E~idence That  an Antibody  Wkick Reacts witk Neoplastic and Non-Neoplastic 
Lympkocytic Cells Is Responsible for tke Effects of Anti-Lympkoma Serums 
in Vitro and in Vivo 
Are the in ~tro and in vivo effects of anti-lymphoma immune serums referable to 
specific antibodies which react directly with the lymphoma cells both in the test tube 
and in the living animal? A  number of observations provide evidence on the point. 
The findings summarized in Table VI, for example, show dearly that absorption of 
two anti-lymphoma immune serums with 6C3HED lymphoma cells greatly diminished 
the ability of these two serums to act upon AKRL1  cells in vi~o and in vitro, and 
similar results were got when a  smaller quantity of AKRL1 cells was employed for 
absorption. Absorption of the serums with erythroeytes from Swiss mice did not alter 
their capacity to act upon the AKRL1 cells either in ~ivo or in vitro.  1 
In an experiment similar to that of Table VI the capacity of IRS 61 :Anti-Lym- 
phoma 6C3HED to act upon 6C3HED cells in vitro  and in vivo was diminished follow- 
ing absorption with 6C3HED  cells, and in a  further experiment the capacity of two 
anti-AKRL1 immune serums  (IRS 55  and IRS 33)  to inhibit growth of implanted 
AKRL1 cells in vivo was diminished following absorption with AKRL1 cells but re- 
mained undiminished following absorption with mouse liver cells. 
Suv~i~al of Lympkoma  Cells during  Many  Hours'  Exposure  in  Vitro  to 
Anti-L  ympkoma Serums in tke Absence of Complement 
The  experiment summarized in Table I  shows dearly that Lymphoma AKRL1 
cells remained viable during exposure for 1 hour at 37°C. to immune serums of three 
types when the hemolytic complement naturally present in the immune serums had 
been inactivated by means of heat. In the experiment of Table VII, q.v., Lymphoma 
AKRL1 cells also remained viable following exposure in vitro during 16 hours at 37°C. 
to each of two "heat-inactivated" anti-lymphoma  immune serums admixed with heated 
guinea pig serum. In two similar experiments, not to be given in detail, AKRL1 cells 
survived 24 hours' exposure to several immune serums admixed with heated normal 
rabbit serum, and in a further experiment 6C3HED cells survived 5 hours' exposure-- 
the longest period tested--to two anti-lymphoma serums to which heated guinea pig 
serum had been added. It is interesting indeed that lymphoma cells should have sur- 
1 It is interesting to note in passing that the unabsorbed specimen of IRS 58, and also the 
specimens absorbed with Swiss erythrocytes and 6C3HED  lymphoma cells, proved quite 
toxic.  All the mice receiving  these specimens became obviously sick  during the injection 
period, manifesting diarrhea, sluggishness, ruffled fur, and a loss of 2 to 4 gm. in weight, and 
three of them died. The test mice that received serum absorbed with AKRL1 cells, however, 
remained sleek and lively during the course of injections and for the week thereafter, becom- 
ing sick and dying only after the development of manifest lymphomatosis. The findings 
suggest that the AKRL1 cells alone absorbed an undefined  "toxic" antibody. Further evi- 
dence  that this "toxic" antibody reacts specifically with some constituent of AKR mouse 
cells was provided by an observation made repeatedly in other experiments, namely that 
AKR mice were notably more susceptible to the "toxic" effects of anti-AKR Lymphoma 
immune serums than were C3H mice. More will be said further on about the toxicity of the 
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vived under such circumstances and promptly begun to proliferate upon implantation 
in new hosts. For the results of the absorption experiments already given make it seem 
probable that the lymphoma cells had absorbed as much or nearly as much antibody 
as they could possibly absorb during the prolonged contact with the immune serums 
in vitro, though whether they had actually done so was not determined in the experi- 
ments cited. Since mouse serum is known to be devoid of one or more of the com- 
ponents  of hemolytic complement (18),  the animals implanted with  the antibody- 
soaked lymphoma cells could hardly be expected to supply this. The findings suggest, 
however, that the mouse host somehow provides conditions that are essential for the 
effectiveness of the anti-lymphoma serums in vivo and that these conditions are dif- 
ferent from those prevailing in the test tube. 
Will Normal Guinea Pig Serum Enhance the Inhibitory Effects of Anti-Lymphoma 
Serums on Mouse Lymphoma Cells in Vivo.~ 
A number of reasons can be cited for supposing that normal guinea pig serum might 
enhance the effects of immune serums on lymphoma cells in vivo. Firstly, it is a  rich 
source of complement, as is well known,  and  this must  be present if such immune 
serums are to act powerfully upon lymphoma cells in vitro, as we have here shown; so 
too in the case of the structural changes brought' about in Brown-Pearce carcinoma 
cells by means of a specific antibody in vitro (19). Secondly, mouse serum lacks one or 
more of the known components of complement (18), as has already been mentioned. 
Thirdly, in a previous study normal guinea pig serum enhanced to some extent the 
effects of an anti-lymphoma immune serum on several types of AKR lymphoma ceils 
in vivo (20). Hence in the next two experiments normal guinea pig serum was given 
along with various anfi-lymphoma serums to learn whether it would enhance their 
effects on lymphoma cells in the living animal. 
Chart 4 shows the results of the first test. The mixture containing IRS 36:Anti- 
AKRL1 and guinea pig serum completely inhibited growth of the Lymphoma AKRL1 
ceils, while that containing IRS 43:Anti-thymus-nodes and guinea pig serum had a 
marked though incomplete inhibitory effect. IRS 39:Anti-AKR kidney and IRS 37: 
Anti-AKR liver, both in mixture with normal guinea pig serum, were devoid of effect 
on the lymphoma cells in vlvo. 
A  direct comparison was made in the experiment of Chart 5.  IRS  11 :Anti-Lym- 
phoma AKRL1, when given alone on the first day to test mice that had been im- 
planted with Lymphoma AKR17 cells, was only moderately inhibitory; when given 
together with  normal guinea  pig serum  the inhibitory effect was  considerably in- 
creased. This was not the ease, however, with the other two anti-lymphoma serums 
employed in the  test; both were as inhibitory when  given alone as when  given in 
mixture with normal guinea pig serum. 
The findings just cited were representative of those obtained in several additional 
experiments. For in these too normal guinea pig serum regularly failed to render in- 
hibitory immune serums that had been produced with normal mouse liver or kidney 
cells as antigens, and in the bulk of instances it did not notably enhance the inhibitory 
effects  of anti-lymphoma immune  serums.  Occasionally, however,  the  addition of 
normal guinea pig serum to anti-lymphoma serums definitely enhanced their inhibitory 
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TABLE  VII 
Survival of AKRLI  Cdls Held  16 Hours in  Vitro in  Contact with Anti-Lymphoma Immune Serums in  the Absence of 
Complement 
In  vitro mixtures 
Lymphoma AKRLI cells  (5 mil.lion/cc:) 
and  unheated  or  heated  gumea p~g 
serum  1:10,  plus  an  equal  part  of 
serum diluted as indicated 
(1) Normal rabbit serum 
(2) IRS 58: anti-Lymphoma AKRLI 
(3) IRS 61:anti-Lymphoma 6C3HED 
Outcome  of tests  for viability 
Mixtures containing unheated 
guinea pig serum, 1:10. 
Final dilutions  of serum 
1:8  1:16  1:32  1:64 
++++  ++++  ++++  ++++ 
o  o  0  o 
o  o  o  o 
Mixtures containing heat-inactivated 
guinea pig serum, 1:10. 
1:8  1:16  1:32  1:64 
++++  ++++  ++++  ++++ 
+++  +++  o*  +++ 
+++  +++  ++++  +++ 
The anti-lymphoma immune serums were heated at 65°C. for 20 minutes immediately before use. Half of the guinea pig serum employed 
was heated at 56°C. for 30 minutes prior to use; subsidiary tests showed that it was devoid of hemolytic capacity for sheep cells sensitized 
with umboceptor. 
Following  incubation for 16 hours, the various in vitro mixtures were centrifuged at 600 l.P.~, for 5 minutes, with resuspension  of the 
sedimented cells in the same volume of BGR. 0.5 cc. of each suspension was implanted at different sites in two AKR test mice. 
The outcome of the viability tests was recorded as follows:- 
++++,  lymphomus in both implanted mice reaching 1.0 cm. across on day 9, enlarging progressively thereafter until death of the host. 
+-t-+  ~ lymphomas  in both implanted mice reaching 1.0 cm. across on day 11, enlarging progressively thereafter until death of the host. 
0  , negative throughout observation period (18 days). 
0*  , negative, anomalous  result probably resulting from technical  error. 
TABLE  VIII 
Tests for Effects of Various Immune Serums on Established Lymphomas of Three Types in  Vivo 
Serums given intraperltoneally to 
mice of respective groups on 
days 6, 7, 8, 9, and 10. 
(I) Nil-untreated controls 
(2) Normal rabbit serum 
Outcome of implantations 
5,000 lymphoma cells  implanted in both groins of four susceptible  mice ((a), (b),  (¢), (d)) 
in each experimental group on day 1 
C3H mice with 
6C3HED lymphomas 
(a)  (b)  (c)  (d) 
+++  ++++  ++++  d9 
+++  +++  +++  ++++ 
C3H mice with 
E9514 lymphomas 
Ca)  (b)  Co)  (d) 
+++  +++  +++  +++ 
+++  +++  +++  d24 
AKR mice with 
AKRL1 lymphomas 
(a)  (b)  (c)  (d) 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
(3) IRS 59:anti-C3H mammary  carci- 
uom~ 
(4)  IRS 62: Anti-Lymphoma E9514 
(5)  "  64:  "  "  6C3HED 
(6)  "  61:  "  "  " 
(7)  "  58:  "  "  AKRLt 
(8)  "  60:  "  "  A1 
(9)  "  63:  "  "  A2 
(10)  "  35:  "  "  AKRI? 
+++  +++  +++  +++ 
o  0  0  o 
o  o  o  ++ 
o  o  ++  +++ 
o  o  +++ 
0  0  +++  h6 
0  0  0  0 
o  o  ++  +++ 
+++  +++  n22  n22 
o  o  o  o 
o  o  ++  +++ 
o  o  o  +++ 
o  o  ++  h6 
o  o  ++  +++ 
o  +++  +++  +++ 
+++  +++  +++  +++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  ++++ 
++++  ++++  ++++  kts 
0  ++++  ++++  hi0 
0  0  0*  d6 
0  +++  +++  +++ 
++++  ++++  ++++  k18 
++++  ++++  ++++  ++++ 
The serums were heated at 65°C. before use.  1.5 cc. of serum was given to each mouse on the 5 successive days, except with  serums IRS 
64, IRS 58, IRS 35, IRS 52 in which the amount was reduced to 1.0 cc. or 0.5 cc. on days 8, 9, and 10 because of manifest toxicity. 
++-}--[-, died before day 20 with subcutaneous tumors and signs of lymphomatosls. 
-]--}-+ , died before day 32  "  "  "  "  "  "  " 
++  ,diedbeforeday44  "  "  "  "  "  "  " 
0  , remained lively and devoid of palpable tumors or signs of lymphomatosis throughout observation period (120 days). 
dg, etc., died on day indicated, not autopsied. 
d24, died with ear infection  and paralysis, day 24. 
h6, died on day indieated--intraperitoneal hemorrhage resulting from injection, proved at autopsy. 
k18, killed  and discarded on 18th day. 
n22, died with anaearca and other signs of nephrotoxic nephritis on day indicated. 
0", died on day 30--groins negative. No gross signs of lymphomatosis at autopsy. CmcR~r 4.  Tests for effects in ~ivo on mouse Lymphoma AKRL1  cells  of  normal  guinea  pig  serum  given alone 
and in mixture with various immune serums.* 
L,R  -  left and right groins, respectively. So, too, in the charts that foUow. 
* Three untreated control mice were also implanted. They developed tumors like those of the  mice in groups 1, 4, and 5, and died on the 
17th and lSth day~. 
** Tumor noted in right groin of Mouse 4 on the 30th day, with death on the 32nd day. Mice 5 and 6 remained devoid of tumors and were 
lively throughout the observation period (50 days). 
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CKARZ 5. Tests  for  e~ects  in  riro  on  Lymphoma AKRL17  ceils  of  immune serums given  as  such  and  mixed  with 
normal  guinea  pig  serum. 
• Rema|ned negstive throughout observatlon period (42 days). 252  EFI~ECTS  01  ~ IMMUNE  SERUMS  ON  LYM~HOMA  CELLS 
IRS 35 :Anti-Lymphoma AKR17  proved notably potent when given in combination 
with  guinea  pig  serum  but  was  largely  devoid  of  effect  when  given  alone. 
Toxicity of the Immune Serums 
As has already become apparent,  a  number of the immune serums used in the present 
work proved toxic for young adult mice when given repeatedly in doses of 0.5 or 1.0 cc. intra- 
peritoneally. The serums varied widely in their ability to induce toxic manifestations, how- 
ever, and their toxicity was in general not proportional to, and in some instances was wholly 
unrelated to, their ability to kill lymphoma ceils in vitro and in vivo. Furthermore the toxic 
maz~festations caused by different immune serums were quite diverse, and there were wide 
differences too in the susceptibility of various mice to the toxic effects, young mice in general 
succumbing much more readily than older weightier ones, while mice of certain breeds, no- 
tablyAKR/JAX, tolerated the immune serums much less well than did mice of other breeds 
e.g., C3H/JAX. 
Numerous  observations provided  evidence that hemolysins acting in conjunction with 
complement were responsible for some of the toxic effects. For example, it was learned early 
in the course of the work that various immune serums could be largely "detoxified" by heat- 
ing them at 56 or 65°C. for 20 minutes. This procedure virtually abolished the ability of the 
serums  to  induce a  more  or less transitory shock-like state  (characterized by respiratory 
distress  and  lassitude,  sometimes accompanied  by  hemoglobinurla)  which  often  followed 
within an hour or 2  after the injection of  the serum intmperitoneally; furthermore when 
normal guinea pig serum was added to a  specimen of heated immune serum, its capacity to 
induce the shock-like state was restored, as many observations showed. But heating did not 
by  any  means  completely  detoxify  the  immune  serums.  Virtually  all  of  these  con- 
rained hemagglutinins as Well as hemolysins, the titers varying from 1:40 to 1:320 or more 
in the numerous tests made.  And anti-erythrocyte serums--produced with either AKR or 
C3H cells--proved by far the most toxic of the serums used in the present work. Thus, when 
heated specimens of the anti-erythrocyte serums were given daily in amounts of 0.25 cc.  or 
less to young adult mice of several breeds, the animals almost regularly died 12 to 24 hours 
after the first or second injection, postmortem examination disclosing as a  rule slight icterus 
together with marked congestion of the lungs and distention of the right side of the heart 
with dark liquid blood and a  very greatly enlarged spleen that was almost black. Mouse 
erythrocytes from animals of various breeds readily absorbed the hemolysins and hemaggiu- 
tinins  from  the  various  immune  serums  in  vitro,  as  many  experiments  showed,  and 
the absorbed serums were devoid of ability to induce the toxic manifestations just described. 
The findings to be given in the next two sections, however, show clearly that attempts to 
detoxify anti-lymphoma immune serums by means of absorption were not always successful. 
Certain of the immune rabbit serums, notably those produced with mouse kidney and 
mouse brain as antigens, often gave rise to anasarca and other signs of "nephrotoxic" nephritis. 
These manifestations usually appeared  several days after a  course of injections had been 
given, and sometimes the animals survived a week or 2 with extreme ascites and subcutaneous 
edema, the kidneys being enlarged and pale and having proliferated giomeruli with greatly 
swollen endothelial and epithelial cells,  as microscopic examinations showed. No systematic 
attempts were made to absorb from the immune serums the antibodies responsible for the 
nephrotoxic effects. 
The toxicity of the anti-erythrocyte, anti-brain, and anti-kidney serums, as just described, 
has special siguifieance; for these serums were all devoid of ability to inhibit growth of the 
several types of lymphoma cells in vivo, as has been shown. Some of the immune serums that S.  C.  MOHOS  AND  3".  G.  KIDD  253 
were effective in v/vo--notably those produced with the lymphoma cells as antigens--also 
proved toxic. The toxicity of different  anti-lymphoma serums  varied widely, however, and 
absorption tests disclosed that in most instances this toxicity was referable to antibodies 
that  reacted with  mouse  erythrocytes. 
Attempts to O~ercome "Established"  Lymphoma Cells of Several Types with 
A nti-L  ymphoma Serums 
In experiments already given (Charts 3 to 5, Tables V and VI), eight anti-lymphoma 
serums, made by injecting the cells of five transplanted mouse lymphomas into rabbits, 
overcame lymphoma ceils of several types in nivo when they were given on the day of 
implantation and on the two succeeding days as well. In the experiments referred to, 
however, the conditions were such as to favor the action of the immune serums; for 
surely these might be expected to overcome a relatively small number of recently im- 
planted (and perhaps specially vulnerable) lymphoma cells more readily than  they 
could overcome the much larger numbers of proliferating lymphoma cells known from 
microscopic studies to be present at the subcutaneously-implanted sites and in the 
viscera of susceptible mice several days after implantation. In the experiments now to 
be described, conditions were much less favorable for the immune serums; for these 
were given after the implanted lymphoma cells had had 5 or 6 days in which to es- 
tablish themselves and proliferate. 
Table VIII shows the results of attempts to influence established lymphomas of 
three  types---6C3HED,  E9514,  and  AKRLl--with  a  number  of  anti-lymphoma 
serums and with an anti-mammary carcinoma serum. The serums were given intra- 
peritoneally on the 6th,  7th,  8th,  9th, and  10th days to C3H and AKR mice (four 
animals in each group, all weighing 24 gin. or more initially) that had been implanted 
in each groin with 5,000 lymphoma cells of one or another of the three types on the 
1st day of the experiment. It can be seen that all the untreated control mice developed 
palpable growths and died with lymphomatosis except for one which died with diar- 
rhea on the 9th day; so too with the mice given normal rabbit serum and those given 
the  anti-mammary carcinoma serum  (IRS 59),  though one of  the  former was lost 
as a result of otitis following trauma and two of the latter died with signs of nephro- 
toxic nephritis on the 22nd day. The seven anti-lymphoma immune serums had quite 
different effects, as the table shows. Taken together they brought about a cure-i.e., 
survival for 120  days without signs of lymphomatosis--in 19  of 26  treated mice in 
which Lymphoma 6C3HED  cells had been implanted, in 14 of 27 treated mice that 
had been implanted with Lymphoma E9514 cells, and in 5 of the 27 treated mice im- 
planted with AKRL1 cells. 
Several of the immune serums  had more or less specific effects. For eY~mple, IRS 62: 
Anti-Lymphoma E9514 proved completely  effective against the ceils of Lymphomas 6C_.3HED 
and E9514 in ~ivo but had no observable  effect on the cells of Lymphoma AKRL1, while 
IRS 63:Anti-Lymphoma A2 was effective against the cells of Lymphoma 6C3I-IED but had 
little or no effect on the cells of the other two lymphomas. It seems especially noteworthy 
that the only serum which notably inhibited the AKRLf cells was LRS 58: Anti-Lymphoma 
AKRL1, and that this serum was less effective against lymphoma cells of the other two types 
than were several of the immune serums  tested in comparison  with it. 254  EFFECTS  OF  IMMUNE SERUMS ON  LYMPHOMA CELLS 
A number of the immune serums, which were given repeatedly in relatively large amounts 
as the table Shows, proved manifestly toxic,  bringing about losses in weight of as much as 
5.0 gin., together with ruffted  fur and sluggishness,  during the period of injections and for 
a few days thereafter. These manifestations proved transitory, however, in the bulk of in- 
stances, though they were so marked in four of the experimental groups that reduced amounts 
of serum were given on days 8, 9, and 10, the details being given in the table. Only one of 
the anti-lymphoma serums (IRS 58:Anti-AKRL1) proved lethal, however;  it brought about 
death in two of the 12 injected animals within a  few hours following  the second  injection, 
while a  third mouse died on the 30th day without gross  evidence of lymphomatosis and 
perhaps as a result of delayed toxic effects. Mention has already been made of the fact that 
two of the mice injected with IRS:59  (anti-mammary carcinoma) died with anasarca and 
other signs of nephrotoxic nephritis on the 22nd day of the experiment; actually most of the 
mice injected with this serum developed ascites and subcutaneous edema during the period 
10 to 17 days, and in some instances the signs were marked; but they proved transitory, 
except in the two instances already noted, and the hosts manifesting them developed lym- 
phomatosls as did the mice of the control groups. In contrast to the serums just mentioned, 
IRS 62:Anti-Lymphoma E9514 was notably devoid of toxicity, the animals receiving this 
serum remaining sleek  and lively and maintaining or increasing their respective weights 
throughout the injection period and thereafter, as dally observations Showed; yet this serum 
completely cured the mice implanted with 6C3HED cells and so too those implanted with 
E9514 cells, in these respects being the most potent of all the serums used in the experiment. 
The same was tree of IRS 63:Anti-Lymphoma A2, which did not induce weight loss or any 
other signs of toxicity but cured all the animals that had been implanted with Lymphoma 
6C3HED cells, as the table shows. 
From the findings just described (Table VIII) it is obvious that the three types of 
lymphoma cells differed notably in susceptibility to the effects of the immune serums 
in v/vo, the AKRL1 cells being much less susceptible (5/27 cures) than those of Lym- 
phomas 6C3HED  (19/26 cures) and E9514  (14/27  cures). The effects in general, it 
may be noted, paralleled those observed in the in v/lro studies already given (Table 
I). 
Chart 6 shows the results of two experiments of similar sort. 
In the first experiment (left hand columns--experimental  groups I to 4) sixteen C3H mice, 
each weighing 28 gln. or more, were implanted with L~mphoma 6C3HED cells, 5,000 in each 
groin. Four of the mice (numbers 1 to 4) were left untreated as controls, and 3 others (Nos. 14 
to 16) were given 2.0 cc. of normal rabbit serum intraperitoneally on the 5th, 6th, 7th, 9th, 
and llth day following implantation (mouse 13, originally included in this group, died within 
an hour following the second intraperitoneal injection with abdominal hemorrhage resulting 
from a rent in one of the mesenteric veins). From this chart it can be seen that subcutaneous 
lymphomas up to 1.0 cm. across appeared at both implantation sites in all 7 mice in these 
groups; furthermore, the lymphomas enlarged progressively and brought about death of the 
animals within 40 days. The results were very different in the remaining mice. Four of these 
(Nos. 5 to 8) were given 1.0 cc. of IRS 61: Anti-Lymphoma 6C3HED, again on the 5th, 6th, 
7th, 9th, and llth days following implantation. These animals maintained their respective 
weights during the period of intraperitoneal injections, as daffy weighing showed,  and they 
remained lively and fleshy and devoid of palpable growths or other signs of lymphomatosis 
throughout the entire observation (120 days); i.e., they were cured. The remaining 4 animals 
(numbers 9 to 12) were given, on each of the injection days, 2.0 cc. of IRS 61 which had been S.  C.  MOHOS  AND  ].  G.  KIDD  255 
CHAXT 6.  Tests for effects of anti-lymphoms immune rabbit serums on "estsblished" lymphomas of two types 
.~.  'o'/.~o. 
The serums  were hested ~t 6S'C. before use. L,R -  left and right groins, respectively. H* Died with intnLperitonea!  hemorrlmge  tmmedi. 
ately following  injection. 
N. no palpable tumot~,--mouse  lively. 
N*, mouse remained lively and devoid of palpable tumors or other signs of lymphomstosis  throughout observation  period (120 dsys). 256  EF]~ECTS OF  I~YI~  SERUMS  ON  LYMPHOMA CELLS 
absorbed  successively with mouse erythrocytes, mouse liver cells,  and  mouse kidney cells. 
Mouse 9 died with abdominal hemorrhage a  few minutes following the final intrapefitoneal 
injection. Mice 10 and  11 did not develop palpable growths and remained lively throughout 
the observation period (120 days). Mouse 12 developed a  palpable tumor in its right groin 
on  the  17th  day  and  died  on  the  32nd  day  with  lymphomatosis.  The  facts  suggest 
that, although the absorbed serum was still remarkably potent, its effectiveness was  dimin- 
ished, though whether the diminution was referable to absorption per se or to the prolonged 
handling of the serum during the procedure is not wholly dear. 
In the experiment summarized in the right hand columns of Chart 6, six AKR mice, all 
weighing 26 gin. or more, were implanted in each groin with 5,000 Lymphoma AKR17 cells, 
three of the animals (Nos. 17 to 19) beingleft untreated as controls while the rest (Nos. 20 to 22) 
were given, on the 5th, 6th, and 7th days following implantation 2.0 cc. of a mixture containing 
equal parts of IRS 35:Anti-Lymphoma AKR17 plus normal guinea pig serum that had been 
concentrated  3:1  by  pervaporation.  The  control  animals  all developed  palpable  growths 
between the 15th and  17th days and died with lymphomatosis. The treated animals, by con- 
trast,  were cured,  as the chart indicates.  Six additional AKR mice were implanted  in this 
experiment with 2,500 Lymphoma AKR17 cells in each groin. Three of these animals (Nos. 
23 to 25)  were left untreated as controls; all died with lymphomatosls before the 35th day. 
The rest were given IRS 34:Anti-Lymphoma AKRL1 pins normal guinea pig serum; two of 
these treated animals were cured while the third developed palpable growths and died with 
lymphomatosis on the 35th day. 
Susceptibility  of Serum-Treated Mice to  Reimplantation with Lymphoma Cdls 
Several experiments were made to learn whether the effects of anti-lymphoma im- 
mune serums in vivo might be influenced or determined  by resistance of the hosts  to 
the transplanted lymphoma cells. 
In the first such experiment, 16 AKR mice were implanted in each groin with 0.2 million 
AKRL1 cells; 8 of the mice were then given 1.0 cc. of heated anti-Lymphoma AKRL1 serum 
on days 1, 2, and 3, and the others were left untreated as controls. The treated animals failed 
to manifest growths during an observation period of 30 days, while the controls all devel- 
oped palpable tumors within 8 days which enlarged progressively and brought about death 
within 14days. On the 30th day, the 8 treated animals were reimplanted in each groin with 
0.2 million AKRL1 cells from the same suspension,  and a second group of control AKR mice 
were also implanted. 8 days later tumors approximately 1.0 cm. across were palpable in both 
groins of all the animals; the growths enlarged progressively until death of the hosts during 
the period 11 to 14 days, the course of events being precisely the same in the controls and in 
the mice that had previously overcome implanted lymphomas as result of serum treatment. 
Five additional experiments were made with mice in which the lymphoma cells had been 
allowed to "establish" themselves during a period of 4 or 5 days and then were overcome as 
result of serum therapy. In the first of these experiments, the six mice of groups 2 and 3 in 
Chart  6, in which Lymphoma 6C3HED cells had  been overcome following serum treatment 
begun on the 5th day, were implanted on the 120th  day with 6C3HED cells, 0.2 million in 
each groin; as controls, 4 normal C3H mice were implanted in the same way. Palpable tumors 
appeared  in all the mice within 8 days, and the growths enlarged progressively thereafter, 
the course of events again being precisely the same in the serum-treated and control animals. 
So too, in the second  test: five serum-treated  mice that had overcome established AKR17 
cells (those of groups 6 and 8 of Chart 6) proved fully as susceptible as did 5 control AKR 
mice to 0.2 million AKR17 cells implanted in each groin. S. C. MOHOS  AND  ]. G.  KIDD  257 
In the three remaining experiments,  the serum-treated mice of the experiments of Table 
VIII were used.  Nineteen of the animals had overcome established 6C3HED cells, 14 had 
overcome established E9514 cells, and 4 had overcome established AKRL1 cells. All were 
implanted on the 120th day following the initial implantations, with lymphoma cells of the 
type previously used, 0.2 million cells being placed in each groin; four control mice were also 
implanted with each of the respective types of lymphoma cells. Again the serum-treated mice 
proved fully susceptible, tumors appearing as promptly and growing as rapidly in them as in 
the respective control animals. 
The findings as a whole provide strong evidence that host resistance had no part 
in the process whereby the lymphoma cells were overcome in the serum-treated mice. 
Limitations  of the Effects of Anti-Lymphoma Serums  on Lymphoma  Cells in  Vivo: 
Comparison with Effects of (a)  Chemotherapeutic Agents  and  (b) Normal 
Guinea Pig Serum 
In the experiments of Table VIII and Chart 6, already described, a number of anti- 
lymphoma serums largely or completely inlaibited the ceils of Lymphomas 6C3HED, 
E9514, and AK_R17 in vivo when they were given to the host animals 5 or 6 days after 
implantation. These  anti-lymphoma serums,  however,  and  others  prepared in  the 
same way, had only transitory and on the whole negligible effects in a  number of 
experiments when they were given to mice with palpable tumors of the three types 
resulting from implantations made 8  to  12  days before therapy was begun.  Under 
such  circumstances, the palpable growths often diminished in size during the first 
few days of serum therapy, but they never disappeared completely, and the animals 
generally survived only a few days longer than did untreated controls or those given 
normal rabbit serum.  In several attempts  to overcome established lymphomas re- 
suiting from implantation of E9514, AKR17, and A1 cells, a number of anti-lymphoma 
immune serums proved no more effective when  given in  combination with normal 
guinea pig serum than when given alone. 
The  effects of anti-lymphoma serums on Lymphoma AKRL1  cells in vi~o were 
even more limited. True, a  number of  the serums regularly and completely inhibited 
large numbers of implanted AKRL1 cells when they were given to the host mice on 
the day of implantation and on the 2 succeeding days as well (see Charts 3 and 4 for 
examples). But in the experiment of Table VIII already cited, six of the seven anti- 
lymphoma serums employed had comparatively little or no effect when  they were 
injected after the lymphoma cdls had become established in new hosts, IRS 58 alone 
proving notably potent. It should be pointed out, however, that this was the only 
antiserum prepared with Lymphoma AKRL1 cells as antigen which was used in the 
experiment of Table VIII; furthermore it was the only such antiserum used in the 
present work in the attempts to overcome established AKRL1 cells in ~i~o. The results 
of a  further  experiment, done  concurrently with  the  experiments of  Chart  6  and 
in the same way, showed dearly that this serum, while acting powerfully against es- 
tablished AKRL1 cells, was toxic for the host animals. 
Hence, it is manifest that the anti-lymphoma serums here used had only a limited 
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were sometimes notably toxic. They share these limitations, it may be noted, with 
all the chemotherapeutic agents which have thus far been critically tested and fuRRy 
reported upon, as scrutiny of the literature shows. 
For example, Skipper, Chapman, and Bell reported in 1951--in extension  of their earlier 
work and that of others (21), including Burchenal and his associates (22)--that aminopterin 
and amethopterin, while  manifestly toxic, were  more effective in ~vo against the cells of 
Lymphoma AK4 than were any of a variety of other therapeutic measures, including x-rays, 
urethan, HN2, colchicine, benzene, potassium arsenite, and 2,6-dlaminopurine, given singly 
and in various combinations; yet all the mice treated by Skipper,  Chapman, and Bell with 
anti-folic acid compounds  died with lymphomatosis before the 35th day (23). Subsequently 
a number of workers have shown that several additional compounds,  notably 8-azaguanine, 
6-mercaptopurine,  and ethionine,  given singly and in combinations with one another and 
with amethopterin, have limited effectiveness against some types of lymphoma Cells in mice 
but no effect at all against other types. For example, Law reported in 1952 that amethopterin 
and 8-azaguanine, although devoid of effect upon several types of lymphoma cells, prolonged 
the survival of susceptible mice implanted with one strain of Lymphoma L1210 cells when 
the two compounds were given on alternate days beginning 24 hours after implantation, and 
that his most effective regimen  brought about a  cure (i.e. survival for 90 days following 
implantation without signs of lymphomatosis)  in 23 per cent of his treated mice (24). Goldin, 
Venditti, Humphreys, and Mantel have reported similar findings in mice  implanted with 
L1210 cells and subsequently treated intensively with amethopterin, sometimes in combina- 
tion with citrovorum factor and other chemical  substances,  though they have now found 
therapy with amethopterin, given alone or in combination with other drugs, largely devoid 
of curative effect on this lymphoma if therapy is delayed until large numbers of the lym- 
phoma cells are proliferating in the implanted host (25). 
Because of the findings noted above  , we did not make a  detailed and systematic 
comparison of the effects of immune serums and chemotherapeutic compounds on the 
lymphomas used in the present study. The results of a  number of experiments made 
it  plain,  however,  that  amethopterin,  8-azaguanine,  azaserine,  6-mercaptopurine, 
and  ethionine, given singly and  in combinations in maximal tolerated  (and  toxic) 
amounts, had little or no effect in v/vo on the ceils of Lymphomas 6C3HED, E9514, 
and AKRL1  when  therapy was given according to the dosages employed by Law 
(24) and instituted 3 days or more following implantation instead of on the following 
day as in his experiments. In several additional experiments the chemotherapeutic 
agents mentioned were given in combination with the immune serums, but the in- 
hibitory effects were not notably greater than those brought about by the immune 
serums alone. 
The effects of immune serums on lymphoma cells in v/so, and  those of chemical 
substances as described above, deserve comparison also with  the ability of normal 
guinea pig serum to bring about the regression of certain lymphomas in v/so (I). It 
should be noted at the outset that the effects of normal guinea pig serum on trans- 
planted lymphoma cells in also are singularly specific. For while normal guinea pig 
serum acted powerfully upon the cells of Lymphomas 6C3HED  and A2 implanted 
in C3H and A/Jax mice respectively, and upon those of the Murphy-Sturm Lympho- 
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Sarcoma 180 or on those of several transplanted mammary carcinomas of C3H mice 
(1), and in a subsequent study it had little or no effect in viva on the cells of any one of 
8 transplanted lymphomas of AKR mice (20).  In more recent tests, made with Dr. 
Michel Haddad, guinea pig serum has furthermore proved essentially devoid of effect 
in viva on the cells of any one of 12 additional mouse lymphomas, including Mecca 
and IA946 of AKR mice, L1210 and L5170 of DBA mice, E9514 and L7688 of C3H 
mice, Lymph0ma 1 of Strong A mice, Lymphoma B14 of C58 mice, and 5 lymphomas 
originating in hybrid AKR X C3H mice and transplanted in this laboratory. Jamieson, 
Ainhis,  and Ryan have lately reported,  however,  that normal guinea pig serum  is 
active in viva against the cells of a  transplanted fibrosarcoma of rats  (26).  Even so, 
it is obvious that normal guinea pig serum is shm-plylimited in its effects by an extraor- 
dinary and unexplained specificity. Yet it acts powerfully indeed against lymphoma 
cells  of the sorts  that are susceptible  to its effects  in viva. For in extension of our 
previous observations (1), recent experience has shown that normal guinea pig serum 
will regularly bring about regression of subcutaneous lymphomas 2  to 3 an.  across 
and of generalized lymphomatosis as well which have resulted from the implantation 
of 6C3HED cells in susceptible C3H mice 12 to 18 days bcmre therapy is begun. It is 
obvious that under such circumstances the effects  of guinea pig serum are far more 
powerful than are those resulting from the administration of immune serums or chem- 
ical substances as described above. 
RECAPITIEATION AND COUNT 
In the  experimental  work here  described,  43  immune  serums  were  prepared  in 
rabbits with antigens consisting of cells procured from mouse tissues of three sorts: 
(a) normal cells from mouse organs and tissues that were presumably devoid of large 
numbers of lymphocytic cells--notably liver, kidney, brain, muscle, whole embryos, 
and  erythrocytes;  (b)  non-neoplastic lymphocytic cells  from  thymuses  and lymph 
nodes of young C3H and AKR mice, and (c) the cells of seven different transplanted 
lymphomas which had originated in C3H, AK_R, and Strong A mice. The various im- 
mune serums were then  tested for capacity to act upon the cells  of several  of the 
transplanted mouse lymphomas under controlled conditions in vitro and in viva. 
Almost all the immune serums promptly killed the various types of lymphoma cells 
in vitro when hemolytic complement was present in the mixtures. The serums varied 
notably in potency, however,  as  titrations  showed,  those in category (a)  being in 
general less potent in vitro than were those in category (b), while those in category (c) 
were generally most potent in the comparative in vitro tests. Absorption procedures 
demonstrated that the immune serums differed qualitatively as well. For mouse eryth- 
rocytes, and cells from a  variety of non-lymphatic mouse organs  also,  readily  ab- 
sorbed the antibodies that were responsible for the in vitro effects on lymphoma cells 
from immune serums prepared with antigens of category (a), but they did not remove 
such antibodies from immune serums made with antigens consisting of non-neoplastic 
and  neoplastic lymphocytic cells  (categories  (b)  and  (c)).  Non-neoplastic  thymus 
and lymph node cells,  however, removed the antibodies responsible for the in vitro 
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lymphoma cells of several types, limited observations indicating that the latter were 
considerably more powerful. 
The in vivo tests provided further indications of specificity. For the immune serums 
of category (a) were all devoid of effect when  they were given intraperitoneally to 
susceptible mice that had been implanted with the respective types of lymphoma cells. 
The immune serums produced with non-neoplastic and neoplastic lymphocytic cells, 
however, often acted powerfully against the lymphoma cells in  vivo. Furthermore, 
the antibodies responsible for the in vivo effects, like those responsible for the in vitro 
effects, were removed upon absorption with lymphoma ceils but not  with  the cells 
of normal mouse organs such a  kidney and liver, or with  mouse  erythrocytes. The 
findings suggest that an  antibody which reacts more or less specifically, with  neo- 
plastic and non-neoplastic lymphocytic ceils of mice was largely responsible for the 
in vivo and in vitro effects of the anti-lymphoma serums. The findings also disclosed 
further  indications of inherent differences in  the various types of lymphoma cells. 
For in several instances immune serums produced with lymphoma cells of a given type 
as antigen proved more powerful against lymphoma cells of that type than did immune 
serums prepared with lymphoma cells of other types as antigens. Furthermore, the 
cells of Lymphomas 6C3HED, E9514, and AKR17 proved much more susceptible to 
the effects of various anti-lymphoma immune serums,  in comparative in vitro  and 
in vivo tests,  than  did the cells of Lymphoma AKRL1. 
Although the lymphoma cells were rapidly killed upon exposure to the anti-lym- 
phoma serums in vitro  in the presence of complement, they survived many hours' 
exposure in vitro  to anti-lymphoma serums  that  had  been heated at 65°C.  for  20 
minutes--a procedure that inactivated hemolytic complement but did not notably 
diminish the capacity of the immune serums to act upon the lymphoma cells in vivo. 
The  findings suggest that  the host organism  somehow participates in  the process 
whereby lymphoma cells are overcome in mice given anti-lymphoma immune serum, 
perhaps by providing some essential "complementary" substance; but they do not 
disclose the precise nature of this participation. Normal guinea pig serum, given along 
with  anti-lymphoma serums  with  the  aim  of providing additional  "complement" 
or perhaps other ancillary factors, occasionally but by no means regularly enhanced 
the effects of the anti-lymphoma immune serums in vi~o. 
Several anti-lymphoma immune serums, when heated at 65°C. for 20 minutes, were 
notably effective against lymphoma cells in vivo while at the same time being devoid 
of toxicity for adult mice. Other pools of anti-lymphoma serums, heated in the same 
way, proved toxic, however, and so too did heated immune serums prepared with 
antigens made from non-neoplastic mouse ceils, notably erythrocytes. In a  number 
of carefully studied instances the toxicity was shown to be due to mouse hemolysins 
and hemagglutinins which could be absorbed from the immune serums with mouse 
erythrocytes and other non-neoplastic mouse cells; but in some instances anti-lym- 
phoma immune serums remained toxic following such absorptions. 
Under favorable conditions the anti-lymphoma serums exhibited quite powerful 
effects against several types of lymphoma cells in vivo. For example, when given intra- 
peritoneally in suitable amounts on the day of implantation and on the 2 succeeding 
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phoma cells of one or another of three types (6C3HED, E9514, AKR17), the various 
anti-lymphoma serums usually brought about death of all  the implanted  cells,  the 
serum-treated animals being fully susceptible to reimplantation later on. Furthermore, 
when selected anti-lymphoma serums were given in suitable amounts to mice with 
established lymphomas resulting from implantations made 5 or 6 days earlier,  they 
frequently brought about a cure--4.e., survival of the hosts without signs of lympho- 
matosis for 90 days or more, while control untreated mice and those given normal 
rabbit  serum  or an  anti-mammary carcinoma serum  regularly  died  with  lympho- 
matosis  before  the  40th  day.  But  the  anti-lymphoma  immune  serums  had  only 
transitory and on the whole negligible  effects when they were injected 8 to 12 days 
following  implantation of lymphoma cells--at a  time, that is to say, when palpable 
growths were present at the implanted sites and great numbers of proliferating lym- 
phoma cells were widely distributed  throughout the organs and tissues of the host 
mice, as microscopic studies showed. 
Scrutiny of the scientific literature showed that the chemotherapeutic agents which 
have  thus  far  been critically evaluated  for effects upon lymphoma cells  in v/vo--- 
notably  amethopterin,  azaguanine,  azaserine,  6-mercaptopurine,  ethionine,  and 
others--have proved largely devoid of effect on lymphoma cells of numerous types, 
and have in each instance displayed sharply limited and, on the whole, quite feeble 
effects against lymphoma cells  of only one or a  few selected types. In a  number of 
experiments done in the course of the present work amethopterin, azaguanine, aza- 
serine, 6-mercaptopurine, and ethionine were given singly and in various combinations 
in maximal tolerated doses to mice that had been implanted several days before with 
lymphoma cells of the several types here used.  Although often toxic for the mouse 
hosts, the chemical substances had little or no effect on the various types of lymphoma 
cells growing in them, their effects being obviously less powerful than those exerted 
by certain of the anti-lymphoma immune serums under comparable circumstances. 
In contrast, normal guinea pig serum, although entirely devoid of effects  on a  con- 
siderable number of mouse lymphomas in dvo, exerts powerful effects in ~ivo ageinst 
the cells of Lymphoma 2 of Strong A mice and those of the Murphy-Sturm lympho- 
sarcoma of rats,  and  it regularly brings about regression of Lymphoma 6C3HED, 
even when given to mice with large subcutaneous lymphomas and generalized lympho- 
matosis resulting from implantations made 12 to 18 days before treatment is begun. 
It seems obvious that normal guinea pig serum works far more powerfully in dvo 
against lymphoma cells of the types that are specially susceptible to its action than 
do any of the immune  serums  or chemotherapeutic substances  described above. 
Manifestly, much remains to be learned about the effects  of immune serums and 
of normal guinea pig serum on lymphoma cells in dvo. Yet these effects are consider- 
able, and to some extent specific, as has been shown. Whether ways can be found to 
enhance them remains to be seen. 
SUMMARY 
Immune serums prepared in rabbits with antigens made from normal mouse 
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cytic  cells  (notably kidney,  liver,  brain,  whole embryos,  and  erythrocytes) 
proved lethal for the ceils of several transplanted mouse lymphomas in ~itro 
in the presence of complement; but these immune serums,  when given intra- 
peritoneaUy in  large  amounts  to  susceptible mice  that  had  been implanted 
subcutaneously with lymphoma cells of one or another of several types, failed 
entirely to inhibit growth of the lymphoma cells in dvo. In contrast, immune 
serums  made  with  cens  procured  from  transplanted  mouse  lymphomas  as 
antigens,  and  those made  with  cells  from  normal  mouse  thymus or lymph 
nodes, acted even more powerfully upon the several types of lymphoma cells 
in dtro than did the immune serums prepared with normal mouse organs,  and 
when given intraperitoneally  to implanted mice they brought about death of 
the lymphoma ceils in ~ivo, the effect being to a  considerable extent specific 
and  referable to an antibody that  reacts with neoplastic and  non-neoplastic 
lymphocytic cells of mice, as absorption experiments disclosed. In comparative 
tests,  furthermore,  the  anti-lymphoms  serums  acted  more powerfully upon 
the lymphoma ceils in vivo than did such chemotherapeutic agents as amethop- 
terin, azaguanine, ethionine, azaserine,  and 6-mercaptopurine, given singly or 
in various combinations in maximal  tolerated  amounts,  though  their  effects 
were not so powerful as those exerted by normal gUinea pig serum on lymphoma 
cells of two types that are susceptible to its action in dvo. 
The significance  of the findings  was briefly discussed. 
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